Overview
Availability
- Professor Avril Robertson is:
- Available for supervision
Qualifications
- Masters (Research), University of St Andrews
- Doctor of Philosophy, University of St Andrews
- Postgraduate Diploma in Higher Education, The University of Queensland
- Postgraduate Diploma in Higher Education, unknown
Works
Search Professor Avril Robertson’s works on UQ eSpace
2015
Journal Article
NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5
Baker, Paul J., Boucher, Dave, Bierschenk, Damien, Tebartz, Christina, Whitney, Paul G., D'Silva, Damian B, Tanzer, Marco J., Monteleone, Mercedes, Robertson, Avril A.B., Cooper, Matthew A., Alvarez-Diaz, Silvia, Herold, Marco J., Bedoui, Sammy, Schroder, Kate and Masters, Seth L. (2015). NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. European Journal of Immunology, 45 (10), 2918-2926. doi: 10.1002/eji.201545655
2015
Journal Article
The inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induce hypertension in mice
Krishnan, S. M., Dowling, J. K., Ling, Y. H., Diep, H., Chan, C. T., Ferens, D., Kett, M. M., Pinar, A., Samuel, C. S., Vinh, A., Arumugam, T. V., Hewitson, T. D., Kemp-Harper, B. K., Robertson, A. A. B., Cooper, M. A., Latz, E., Mansell, A., Sobey, C. G. and Drummond, G. R. (2015). The inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induce hypertension in mice. British Journal of Pharmacology, 173 (4), 752-765. doi: 10.1111/bph.13230
2015
Journal Article
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, Rebecca C., Robertson, Avril A. B., Chae, Jae Jin, Higgins, Sarah C., Muñoz-Planillo, Raúl, Inserra, Marco C., Vetter, Irina, Dungan, Lara S., Monks, Brian G., Stütz, Andrea, Croker, Daniel E., Butler, Mark S., Haneklaus, Moritz, Sutton, Caroline E., Núñez, Gabriel, Latz, Eicke, Kästner, Daniel L., Mills, Kingston H. G., Masters, Seth L., Schroder, Kate, Cooper, Matthew A. and O'Neill, Luke A. J. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 21 (3), 248-257. doi: 10.1038/nm.3806
2015
Conference Publication
Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASH
Mridha, Auvro R., Wree, Alexander, Robertson, Avril A., Teoh, Narci C., Cooper, Matthew A., Feldstein, Ariel E. and Farrell, Geoffrey C. (2015). Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASH. 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, United States, 13-17 November 2015. Hoboken, NJ, United States: John Wiley & Sons. doi: 10.1002/hep.28175
2015
Conference Publication
Novel compound cytokine release inhibitory drug 3 (CRID3) inhibits the NLRP3 inflammasome in rheumatoid arthritis
McGarry, T., Coll, R.C., Robertson, A.A.B., Cooper, M.A., O’Neill, L.A., Veale, D.J. and Fearon, U. (2015). Novel compound cytokine release inhibitory drug 3 (CRID3) inhibits the NLRP3 inflammasome in rheumatoid arthritis. 35th European Workshop for Rheumatology Research, Budapest, Hungary, 5-7 March 2015. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2015-207259.144
2015
Conference Publication
Activation of Redox-Sensitive Inflammasomes Underlies the Biological Phenotype of Myelodysplastic Syndromes
Basiorka, A., Mcgraw, K., Eksioglu, E., Chen, X., Johnson, J., Padron, E., Komrokji, R., Sokol, L., Coll, R., O'Neill, L., Cooper, M., Robertson, A., Wei, S. and List, A. (2015). Activation of Redox-Sensitive Inflammasomes Underlies the Biological Phenotype of Myelodysplastic Syndromes. 13th International Symposium on Myelodysplastic Syndromes (MDS), Washington DC, United States, Apr 29-May 02, 2015. Kidlington, Oxford, United Kingdom: Pergamon Press. doi: 10.1016/S0145-2126(15)30033-3
2015
Conference Publication
An optimized whole blood assay measuring expression and activity of NLRP3-, NLRC4 and AIM2-inflammasomes
Grinstein, L., Luksch, H., Robertson, A. A. B., Cooper, M. A., Winkler, S. and Rösen-Wolff, A. (2015). An optimized whole blood assay measuring expression and activity of NLRP3-, NLRC4 and AIM2-inflammasomes. 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases, Dresden, Germany, 30 September - 3 October 2015. BMC. doi: 10.1186/1546-0096-13-S1-O51
2015
Conference Publication
The effect of novel compound MCC950 On the NLRP3 inflammasome in the RA joint
McGarry, T., Robertson, A. A., Orr, C., Coll, R. C., Cooper, M. A., O'Neill, L. A., Veale, D. J. and Fearon, U. (2015). The effect of novel compound MCC950 On the NLRP3 inflammasome in the RA joint. Annual European Congress of Rheumatology, Rome, Italy, 10-13 July 2015. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2015-eular.3985
2015
Conference Publication
Selective inhibition of the NLRP3 inflammasome dose-dependently reduces infarct size and preserves cardiac function in a porcine model of myocardial infarction
Van Hout, G. P. J., Bosch, L., Ellenbroek, G. H. J. M., Cooper, M., Van Solinge, W. W., De Jager, S. C. A., Robertson, A., Pasterkamp, G. and Hoefer, I. E. (2015). Selective inhibition of the NLRP3 inflammasome dose-dependently reduces infarct size and preserves cardiac function in a porcine model of myocardial infarction. Congress of the European Society of Cardiology (ESC), London, United Kingdom, 29 August-2 September 2015. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/eurheartj/ehv400
2014
Journal Article
Natural product and natural product derived drugs in clinical trials
Butler, Mark S., Robertson, Avril A. B. and Cooper, Matthew A. (2014). Natural product and natural product derived drugs in clinical trials. Natural Product Reports, 31 (11), 1612-1661. doi: 10.1039/c4np00064a
2014
Journal Article
Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction
Greenhill, Claire J., Jones, Gareth W., Nowell, Mari A., Newton, Zarabeth, Harvey, Ann K., Moideen, Abdul N., Collins, Fraser L., Bloom, Anja C., Coll, Rebecca C., Robertson, Avril A. B., Cooper, Matthew A., Rosas, Marcela, Taylor, Philip R., O'Neill, Luke A., Humphreys, Ian R., Williams, Anwen S. and Jones, Simon A. (2014). Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy, 16 (4) 419. doi: 10.1186/s13075-014-0419-y
2014
Conference Publication
Control of the human Th1 response via autocrine complement-regulated NLRP3 inflammasome activation within CD4(+) T cells
Arbore, Giuseppina, Fara, Antonella F., Coll, Rebecca, Robertson, Avril, Cooper, Matthew, O'Neill, Luke A. J., Lavender, Paul, Cope, Andrew, Lachmann, Helen J. and Kemper, Claudia (2014). Control of the human Th1 response via autocrine complement-regulated NLRP3 inflammasome activation within CD4(+) T cells. 25th International Complement Workshop, Rio de Janeiro, Brazil, 14-18 September 2014. Kidlington, Oxford, United Kingdom: Pergamon Press. doi: 10.1016/j.molimm.2014.07.010
2014
Conference Publication
What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH
Gan, L. T., Van Rooyen, D. M., Cooper, M., Robertson, A., Masters, S., Teoh, N. and Farrell, G. (2014). What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH. Australian Gastroenterology Week, Broadbeach, QLD, Australia, 22-24 october 2014. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12736
2014
Conference Publication
Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis
McGarry, Trudy, Connolly, Mary, Coll, Rebecca C., Robertson, Avril A. B., Cooper, Matthew A., O'Neill, Luke A., Veale, Douglas J. and Fearon, Ursula (2014). Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis. 78th Annual Meeting of the American College of Rheumatology/49th Annual Meeting of the Association of Rheumatology Health Professionals, Boston, MA United States, 14-19 November 2014. Hoboken, NJ United States: John Wiley and Sons.
2014
Conference Publication
MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases
Coll, Rebecca C., Robertson, Avril A. B., Chae, Jae Jin, Higgins, Sarah C., Dungan, Lara S., Munoz-Planillo, Raul, Monks, Brian G., Croker, Daniel E., Sutton, Caroline E., Stutz, Andrea, Nunez, Gabriel, Latz, Eicke, Kastner, Daniel L., Mills, Kingston H. G., Masters, Seth L., Schroder, Kate, Cooper, Matt A. and O'Neill, Luke A. J. (2014). MCC950 is a potent and specific inhibitor of the NLRP3 inflammasome and a novel potential therapeutic for NLRP3 driven diseases. 2nd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Melbourne Australia, Oct 26-29, 2014. London United Kingdom: Academic Press. doi: 10.1016/j.cyto.2014.07.037
2014
Conference Publication
Combined in Vivo and in Vitro Analyses Identify the Caspase-1/trpm2 Axis as a Contributor to Neutrophil-Driven Airway Inflammation in Cystic Fibrosis
Forrest, O., Ingersoll, S., Robertson, A. A., Preininger, M., Laval, J., Brown, M., O'Neill, L., Cooper, M. A., Tangpricha, V and Tirouvanziam, R. (2014). Combined in Vivo and in Vitro Analyses Identify the Caspase-1/trpm2 Axis as a Contributor to Neutrophil-Driven Airway Inflammation in Cystic Fibrosis. The 28th Annual North American Cystic Fibrosis Conference, Atlanta, GA United States, 9-11 October 2014. Hoboken, NJ United States: John Wiley and Sons. doi: 10.1002/ppul.23108
2014
Conference Publication
Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia
Dempsey, Colin, Coll, Rebecca, Robertson, Avril, Cooper, Matthew, O'Neill, Luke and Lynch, Marina (2014). Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia. 12th International Congress of Neuroimmunology (ISNI), Mainz Germany, 9-13 November 2014. AMSTERDAM: ELSEVIER SCIENCE BV. doi: 10.1016/j.jneuroim.2014.08.393
2013
Journal Article
Erratum: The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes
Coll, R. C., Robertson, A. A.B., Butler, M., Cooper, M. and O'Neill, L. A.J. (2013). Erratum: The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE, 8 (7) e29539. doi: 10.1371/annotation/78d328b9-2c8c-4978-84b1-7e6a0b12ada1
2013
Journal Article
Efficient synthesis of anacardic acid analogues and their antibacterial activities
Mamidyala, Sreeman K., Ramu, Soumya, Huang, Johnny X., Robertson, Avril A. B. and Cooper, Matthew A. (2013). Efficient synthesis of anacardic acid analogues and their antibacterial activities. Bioorganic & Medicinal Chemistry Letters, 23 (6), 1667-1670. doi: 10.1016/j.bmcl.2013.01.074
2011
Journal Article
The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes
Coll, Rebecca C., Robertson, Avril, Butler, Mark, Cooper, Matthew and O'Neill, Luke A. J. (2011). The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE, 6 (12) e29539, e29539. doi: 10.1371/journal.pone.0029539
Funding
Current funding
Supervision
Availability
- Professor Avril Robertson is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Breaking the chain of inflammation through targetting NLR proteins
Principal Advisor
Other advisors: Professor David Ascher
-
Doctor Philosophy
Targeting Deadly Mycotic Infection
Principal Advisor
Other advisors: Dr Kylie Agnew-Francis, Professor James Fraser
-
Doctor Philosophy
Therapeutic Resolution of Inflammation in the Central Nervous System for Neuroprotection in Parkinson's Disease
Principal Advisor
Other advisors: Professor David Ascher
-
Doctor Philosophy
Targetting Candida Auris
Principal Advisor
Other advisors: Dr Kylie Agnew-Francis, Professor James Fraser
-
Doctor Philosophy
Aiming at Inflammasomes
Principal Advisor
-
Doctor Philosophy
Biosimilar litigation and market entry
Associate Advisor
Other advisors: Emeritus Professor Stephen Mahler, Dr Lisette Pregelj
-
Doctor Philosophy
The role of metabolic adaptation for virulence and persistence of Haemophilus influenzae in the host
Associate Advisor
Other advisors: Professor Ulrike Kappler
-
Doctor Philosophy
Inflammasome inhibitors in disease: Is there a therapeutic trade-off of compromised host defence?
Associate Advisor
Other advisors: Professor Kate Schroder, Dr Sabrina Sofia Burgener
-
Master Philosophy
Therapeutic targetting of proteins involved in Toll-like receptor signalling
Associate Advisor
Other advisors: Professor Bostjan Kobe
-
Doctor Philosophy
Antifungal agents to target disseminated mycoses
Associate Advisor
Other advisors: Dr Kylie Agnew-Francis, Professor James Fraser
Completed supervision
-
2023
Doctor Philosophy
Targeting NLRP3 and Dopamine Receptors for Treatment Resistant Depression
Principal Advisor
Other advisors: Associate Professor Susannah Tye
-
2023
Doctor Philosophy
Kinase Inhibitors for the Treatment of Inflammatory Disease
Principal Advisor
Other advisors: Professor Bostjan Kobe
-
2020
Doctor Philosophy
Teaching Old Molecules New Tricks: Repurposing Investigational Drugs as Chemical Probes
Principal Advisor
-
2017
Doctor Philosophy
Synthesis and biological activity of sulfonylurea derivatives as NLRP3 inhibitors
Principal Advisor
-
2023
Doctor Philosophy
Biomarkers of Treatment-Resistant Depression and Predictors of Antidepressant Response
Associate Advisor
Other advisors: Associate Professor Susannah Tye
-
2023
Doctor Philosophy
Decontamination of fentanyl and fentanyl analogues
Associate Advisor
Other advisors: Professor Joanne Blanchfield
-
2019
Doctor Philosophy
Novel antifungals selectively targeting the purine metabolic pathway
Associate Advisor
Other advisors: Professor James Fraser, Professor Bostjan Kobe
-
2019
Doctor Philosophy
Pharmacological targeting of the inflammasome: towards novel therapeutics for Parkinson's disease
Associate Advisor
Other advisors: Dr Richard Gordon, Professor Trent Woodruff
Media
Enquiries
For media enquiries about Professor Avril Robertson's areas of expertise, story ideas and help finding experts, contact our Media team: